JP7293209B2 - 医薬剤形 - Google Patents

医薬剤形 Download PDF

Info

Publication number
JP7293209B2
JP7293209B2 JP2020518798A JP2020518798A JP7293209B2 JP 7293209 B2 JP7293209 B2 JP 7293209B2 JP 2020518798 A JP2020518798 A JP 2020518798A JP 2020518798 A JP2020518798 A JP 2020518798A JP 7293209 B2 JP7293209 B2 JP 7293209B2
Authority
JP
Japan
Prior art keywords
active agent
matrix formulation
sustained release
core
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020518798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500316A5 (https=
JP2021500316A (ja
Inventor
アクジャ，オズギュル
ハリス，ステファン
マニオン，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of JP2021500316A publication Critical patent/JP2021500316A/ja
Publication of JP2021500316A5 publication Critical patent/JP2021500316A5/ja
Application granted granted Critical
Publication of JP7293209B2 publication Critical patent/JP7293209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020518798A 2017-10-20 2018-10-19 医薬剤形 Active JP7293209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574978P 2017-10-20 2017-10-20
US62/574,978 2017-10-20
PCT/US2018/056724 WO2019079729A1 (en) 2017-10-20 2018-10-19 PHARMACEUTICAL DOSAGE FORMS

Publications (3)

Publication Number Publication Date
JP2021500316A JP2021500316A (ja) 2021-01-07
JP2021500316A5 JP2021500316A5 (https=) 2021-11-04
JP7293209B2 true JP7293209B2 (ja) 2023-06-19

Family

ID=66173867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020518798A Active JP7293209B2 (ja) 2017-10-20 2018-10-19 医薬剤形

Country Status (6)

Country Link
US (2) US12053464B2 (https=)
EP (1) EP3697393A4 (https=)
JP (1) JP7293209B2 (https=)
AU (1) AU2018351502B2 (https=)
CA (1) CA3075292A1 (https=)
WO (1) WO2019079729A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US12053464B2 (en) * 2017-10-20 2024-08-06 Purdue Pharma L.P. Pharmaceutical dosage forms

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517050A (ja) 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
JP2010501543A (ja) 2006-08-25 2010-01-21 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド鎮痛薬を含む不正改変抵抗性経口医薬剤形
JP2014500304A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ 被覆不正改変抵抗性制御放出剤形
JP2014526497A (ja) 2011-09-16 2014-10-06 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
US20160106735A1 (en) 2014-10-17 2016-04-21 Purdue Pharma L.P. Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
JP2017501228A (ja) 2013-12-23 2017-01-12 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド拮抗薬製剤
JP2017526719A (ja) 2014-09-12 2017-09-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性多幸症を減弱するためのシステム及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
ES2270982T3 (es) * 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA2874604A1 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
EP2079456B1 (en) * 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
ES2482168T3 (es) * 2008-07-31 2014-08-01 Universität Ulm Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
NZ597283A (en) * 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
KR102196741B1 (ko) * 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
US20160220498A1 (en) * 2015-01-29 2016-08-04 Aneesh SONI Fully or partially biodegradable device for controlled drug delivery
JP2017211168A (ja) 2016-05-27 2017-11-30 シャープ株式会社 冷蔵庫、および広告表示プログラム
US20190054024A1 (en) * 2017-08-16 2019-02-21 HUMANWELL PHARMACEUTICAL US, Inc. Solid Dosage Forms
US12053464B2 (en) * 2017-10-20 2024-08-06 Purdue Pharma L.P. Pharmaceutical dosage forms

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517050A (ja) 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
JP2010501543A (ja) 2006-08-25 2010-01-21 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド鎮痛薬を含む不正改変抵抗性経口医薬剤形
JP2014500304A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ 被覆不正改変抵抗性制御放出剤形
JP2014526497A (ja) 2011-09-16 2014-10-06 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
JP2017501228A (ja) 2013-12-23 2017-01-12 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド拮抗薬製剤
JP2017526719A (ja) 2014-09-12 2017-09-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性多幸症を減弱するためのシステム及び方法
US20160106735A1 (en) 2014-10-17 2016-04-21 Purdue Pharma L.P. Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response

Also Published As

Publication number Publication date
AU2018351502A1 (en) 2020-03-26
CA3075292A1 (en) 2019-04-25
AU2018351502B2 (en) 2024-09-05
US20250017917A1 (en) 2025-01-16
EP3697393A4 (en) 2021-10-13
US20210205295A1 (en) 2021-07-08
US12053464B2 (en) 2024-08-06
WO2019079729A1 (en) 2019-04-25
EP3697393A1 (en) 2020-08-26
JP2021500316A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
US9895317B2 (en) Tamper resistant solid oral dosage forms
EP1694260B1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
CA2720108C (en) Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2838516B1 (en) Immediate release, abuse deterrent pharmaceutical compositions
CA2798884C (en) Manufacturing of active-free granules and tablets comprising the same
US11446293B2 (en) Extended release, abuse deterrent dosage forms
CA2798885C (en) Combination of active loaded granules with additional actives
US20250017917A1 (en) Pharmaceutical dosage forms
WO2012007159A2 (en) Novel gastro-retentive dosage forms
CN101010072A (zh) 具有与剂量成比例的稳态Cave和AUC并且小于与剂量成比例的单剂量CMAX的阿片类物质剂量形式
US20240269078A1 (en) Pharmaceutical dosage forms
AU2017239544A1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
KR20190028656A (ko) 내마모성 오피오이드 제형
CA3071261A1 (en) Oral tablet formulations
HK1189510B (en) Tamper resistant solid oral dosage forms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230410

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230418

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230607

R150 Certificate of patent or registration of utility model

Ref document number: 7293209

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150